← Human Trials & Peer-Reviewed Studies
ANGIOTENSIN II FOR CATECHOLAMINE-RESISTANT VASODILATORY SHOCK IN PATIENTS WITH ACUTE KIDNEY INJURY: A POST HOC ANALYSIS OF THE ATHOS-3 TRIAL
Plain-language guide to PMID 39671552 (2025): placebo-controlled randomized controlled trial study of Angiotensin II in 3 patients.
Key Facts
- PMID
- 39671552
- Journal
- Shock (Augusta, Ga.)
- Year
- 2025
- Study type
- Randomized Controlled Trial
- Authors
- Chaba A et al. (8 authors)
- DOI
- 10.1097/SHK.0000000000002481
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Angiotensin II.
The role of angiotensin II (ANGII) in this setting is unclear.
Methods: the researchers conducted a post hoc analysis of the Angiotensin II for the Treatment of High-Output Shock (ATHOS) 3 trial which assessed the effect of Intravenous ANG II or placebo in patients with refractory vasodilatory shock in 75 intensive care units across nine countries in North America, Australasia, and Europe.
Who Took Part
According to the abstract, 3 patients were involved.
By PubMed's age tags, the people studied were middle-aged adults and older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized and placebo-controlled study.
Random assignment meant chance, not the researchers, decided who got Angiotensin II and who got the comparison, which limits bias.
Some patients received a placebo instead of Angiotensin II, giving a reference point.
What Was Measured
Methods: the researchers conducted a post hoc analysis of the Angiotensin II for the Treatment of High-Output Shock (ATHOS) 3 trial which assessed the effect of Intravenous ANG II or placebo in patients with refractory vasodilatory shock in 75 intensive care units across nine countries in North America, Australasia, and Europe.
The researchers included patients with all stages AKI at initiation of ANG II or placebo and assessed 28-day mortality as primary outcome.
The subject headings attached to it are Acute Kidney Injury, Angiotensin II, Catecholamines and Shock.
What This Means in Plain Language
The paper is a randomized and placebo-controlled study of Angiotensin II in 3 patients.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2025 (Shock (Augusta, Ga.)), a journal based in United States.
More context: the Angiotensin II compound page, all human trials.
Our Notes on the Compound
Angiotensin II: An 8-amino-acid hormone that narrows blood vessels; synthetic angiotensin II (Giapreza) is used for low blood pressure in shock.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.